- Home
- ANAB vs BFST Comparison
ANAB vs BFST Comparison
Compare ANAB & BFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- BFST
- Stock Information
- Founded
- ANAB 2005
- BFST 2006
- Country
- ANAB United States
- BFST United States
- Employees
- ANAB N/A
- BFST N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- BFST Major Banks
- Sector
- ANAB Health Care
- BFST Finance
- Exchange
- ANAB Nasdaq
- BFST Nasdaq
- Market Cap
- ANAB 630.2M
- BFST 722.6M
- IPO Year
- ANAB 2017
- BFST 2018
- Fundamental
- Price
- ANAB $21.08
- BFST $24.63
- Analyst Decision
- ANAB Buy
- BFST Strong Buy
- Analyst Count
- ANAB 10
- BFST 3
- Target Price
- ANAB $48.00
- BFST $30.00
- AVG Volume (30 Days)
- ANAB 515.2K
- BFST 81.9K
- Earning Date
- ANAB 11-04-2025
- BFST 10-23-2025
- Dividend Yield
- ANAB N/A
- BFST 2.29%
- EPS Growth
- ANAB N/A
- BFST 3.92
- EPS
- ANAB N/A
- BFST 2.51
- Revenue
- ANAB $123,164,000.00
- BFST $291,096,000.00
- Revenue This Year
- ANAB $11.40
- BFST $25.00
- Revenue Next Year
- ANAB $8.17
- BFST $17.32
- P/E Ratio
- ANAB N/A
- BFST $9.72
- Revenue Growth
- ANAB 304.17
- BFST 17.48
- 52 Week Low
- ANAB $12.21
- BFST $20.07
- 52 Week High
- ANAB $39.50
- BFST $30.30
- Technical
- Relative Strength Index (RSI)
- ANAB 47.97
- BFST 50.31
- Support Level
- ANAB $17.11
- BFST $23.76
- Resistance Level
- ANAB $24.07
- BFST $24.84
- Average True Range (ATR)
- ANAB 1.49
- BFST 0.56
- MACD
- ANAB -0.03
- BFST -0.10
- Stochastic Oscillator
- ANAB 57.03
- BFST 39.73
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.